Back to results
US 2023/0407332 A1Published application
Modified adenoviruses
AssigneeGritstone Bio, Inc.
InventorsKarin Jooss, Ciaran Daniel Scallan, Leonid Gitlin
Life of this patent
Estimating the term…
Abstract
Compositions include modified adenoviruses. Nucleotides, cells, and methods associated with the compositions, including their use as vaccines. Viral vectors using a TET promoter system and methods of producing viruses having the same.
Claims37
1-145. (canceled)
An isolated cell comprising an adenovirus vector, wherein the adenovirus vector comprises:
- an adenoviral backbone comprising one or more genes or regulatory sequences of an adenovirus genome,
- wherein the adenoviral backbone comprises a partially deleted E4 gene with reference to the adenovirus genome,
- wherein the partially deleted E4 gene comprises a partially-deleted E4orf2 region, a deleted E4orf3 region, and a partially-deleted E4orf4 region, and
- wherein the adenovirus vector further comprises a cassette, the cassette comprising:
- (1) at least one payload nucleic acid sequence, optionally wherein the at least one payload nucleic acid sequence encodes a polypeptide, optionally wherein the polypeptide comprises an antigen, optionally wherein the antigen comprises:
- (a) a MHC class I epitope,
- (b) a MHC class II epitope,
- (c) an epitope capable of stimulating a B cell response, or
- (d) a combination thereof, and
- optionally wherein the at least one payload nucleic acid sequence further comprises a 5′ linker sequence and/or a 3′ linker sequence, and optionally wherein;
- (2) at least one promoter sequence operably linked to the at least one payload nucleic acid sequence,
- (3) optionally, at least one universal MHC class II antigen-encoding nucleic acid sequence;
- (4) optionally, at least one GPGPG-encoding linker sequence (SEQ ID NO:56);
- and
- (5) optionally, at least one polyadenylation sequence.
12 more elements
A method of manufacturing an adenovirus vector, the method comprising:
- (A) one or both of (i) transfecting a plasmid sequence comprising the adenovirus vector into a host cell, and (ii) infecting a host cell with an adenovirus comprising the adenovirus vector,
- wherein the adenovirus vector comprises:
- an adenoviral backbone comprising one or more genes or regulatory sequences of an adenovirus genome,
- wherein the adenoviral backbone comprises a partially deleted E4 gene with reference to the adenovirus genome,
- wherein the partially deleted E4 gene comprises a partially-deleted E4orf2 region, a deleted E4orf3 region, and
- a partially-deleted E4orf4 region, and
- optionally, wherein the adenovirus vector further comprises a cassette, the cassette comprising:
- (1) at least one payload nucleic acid sequence, optionally wherein the at least one payload nucleic acid sequence encodes a polypeptide, optionally wherein the polypeptide comprises an antigen, optionally wherein the antigen comprises:
- (a) a MHC class I epitope,
- (b) a MHC class II epitope,
- (c) an epitope capable of stimulating a B cell response, or
- (d) a combination thereof, and
- optionally wherein the at least one payload nucleic acid sequence further comprises a 5′ linker sequence and/or a 3′ linker sequence, and optionally wherein;
- (2) at least one promoter sequence operably linked to the at least one payload nucleic acid sequence,
- (3) optionally, at least one universal MHC class II antigen-encoding nucleic acid sequence;
- (4) optionally, at least one GPGPG-encoding linker sequence (SEQ ID NO:56);
- and
- (5) optionally, at least one polyadenylation sequence;
- and
- (B) isolating the adenovirus vector from the host cell.
17 more elements
Dependencies are inferred from the claim text.